SUSQUEHANNA INTERNATIONAL GROUP, LLP - BROOKLYN IMMUNOTHERAPEUTICS ownership

BROOKLYN IMMUNOTHERAPEUTICS's ticker is BTX and the CUSIP is 114082100. A total of 61 filers reported holding BROOKLYN IMMUNOTHERAPEUTICS in Q4 2021. The put-call ratio across all filers is 0.31 and the average weighting 0.1%.

Quarter-by-quarter ownership
SUSQUEHANNA INTERNATIONAL GROUP, LLP ownership history of BROOKLYN IMMUNOTHERAPEUTICS
ValueSharesWeighting
Q3 2022$8,000
-63.6%
34,223
-18.2%
0.00%
Q2 2022$22,000
-51.1%
41,813
+91.8%
0.00%
Q1 2022$45,000
-95.9%
21,800
-91.6%
0.00%
Q4 2021$1,088,000
-42.3%
260,800
+28.7%
0.00%
Q3 2021$1,884,000
-63.2%
202,590
-28.7%
0.00%
Q2 2021$5,114,000283,9720.00%
Other shareholders
BROOKLYN IMMUNOTHERAPEUTICS shareholders Q4 2021
NameSharesValueWeighting ↓
Cypress Point Wealth Management, LLC 1,887,509$977,0001.71%
Naviter Wealth, LLC 1,572,803$814,0000.33%
ARMISTICE CAPITAL, LLC 4,342,561$2,248,0000.04%
INVERNESS COUNSEL LLC /NY/ 1,210,537$627,0000.04%
Ground Swell Capital, LLC 13,616$7,0000.01%
BALDWIN BROTHERS LLC/MA 40,604$21,0000.00%
Allegheny Financial Group LTD 11,595$6,0000.00%
Ergoteles LLC 145,500$75,0000.00%
Renaissance Technologies 1,215,800$629,0000.00%
Carmichael Hill & Associates, Inc. 1,500$1,0000.00%
View complete list of BROOKLYN IMMUNOTHERAPEUTICS shareholders